Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company raised its 2026 sales and profit outlook, but shares fell as investors focused on weaker-than-expected Wegovy pill sales and another setback for obesity drug CagriSema.

Raccontata dawww1.folha.uol.com.brcnbc.cominvestors.combenzinga.comeconomictimes.indiatimes.comendpoints.newsfiercepharma.com